Home > News > Selecta's Series B Adds $15M to Advance Targeted Nanoparticles
February 25th, 2009
Selecta's Series B Adds $15M to Advance Targeted Nanoparticles
Abstract:
Financings Roundup Founded in late 2007 to develop a technology platform that combines discoveries in immunobiology with advances in nanotechnology, Selecta Biosciences Inc. is ready to start moving its program toward the clinic thanks to a $15.1 million Series B round.
"We were gratified to find a very receptive audience at a very difficult time," said Robert Bratzler, executive chairman of the Watertown, Mass.-based firm. He called the Series B "our first substantial round," following $2.5 million in seed funding in May 2008 from Polaris Venture Partners and Flagship Ventures.
Both of those investors returned for the Series B, joined by NanoDimension, a VC firm that focuses on nanotechnologies, and individual investor Timothy A. Springer, a professor of pathology at Harvard Medical School and previous founder of LeukoSite Inc., which was acquired by Millennium Pharmaceuticals Inc. in 1999.
Source:
tmcnet.com
Bookmark:
| Related News Press |
News and information
Sensors innovations for smart lithium-based batteries: advancements, opportunities, and potential challenges August 8th, 2025
Deciphering local microstrain-induced optimization of asymmetric Fe single atomic sites for efficient oxygen reduction August 8th, 2025
Lab to industry: InSe wafer-scale breakthrough for future electronics August 8th, 2025
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Sensors innovations for smart lithium-based batteries: advancements, opportunities, and potential challenges August 8th, 2025
Deciphering local microstrain-induced optimization of asymmetric Fe single atomic sites for efficient oxygen reduction August 8th, 2025
Japan launches fully domestically produced quantum computer: Expo visitors to experience quantum computing firsthand August 8th, 2025
ICFO researchers overcome long-standing bottleneck in single photon detection with twisted 2D materials August 8th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||